Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population

[1]  P. Baiocco,et al.  Dimethyl Fumarate Reduces Microglia Functional Response to Tissue Damage and Favors Brain Iron Homeostasis , 2019, Neuroscience.

[2]  S. Gautam,et al.  Risk factors for lymphopenia in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate , 2019, Journal of Neurology.

[3]  Jeffrey A. Cohen,et al.  Lymphocyte counts and infection rates , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[4]  M. Trojano,et al.  Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort , 2019, Front. Immunol..

[5]  E. Martínez-Cáceres,et al.  Optimal response to dimethyl fumarate is mediated by a reduction of Th1‐like Th17 cells after 3 months of treatment , 2019, CNS neuroscience & therapeutics.

[6]  R. Henry,et al.  Silent progression in disease activity–free relapsing multiple sclerosis , 2019, Annals of neurology.

[7]  D. Arnold,et al.  Effect of dimethyl fumarate on lymphocytes in RRMS , 2019, Neurology.

[8]  E. Rodríguez-Martín,et al.  Factors associated with dimethyl fumarate-induced lymphopenia , 2019, Journal of the Neurological Sciences.

[9]  W. Brück,et al.  Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis , 2019, Brain pathology.

[10]  G. Buckle,et al.  Lymphopenia and DMTs for relapsing forms of MS , 2019, Neurology. Clinical practice.

[11]  S. Presas-Rodríguez,et al.  Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients , 2018, CNS neuroscience & therapeutics.

[12]  R. Hupperts,et al.  Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies. , 2018, Autoimmunity reviews.

[13]  T. Ziemssen,et al.  Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients , 2018, Front. Immunol..

[14]  P. Gallo,et al.  Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient. , 2018, Multiple sclerosis and related disorders.

[15]  H. Westerhoff,et al.  Predictable Irreversible Switching Between Acute and Chronic Inflammation , 2018, Front. Immunol..

[16]  J. Greenstein.  Diffuse dermatophytosis occurring on dimethyl fumarate therapy , 2018, Multiple sclerosis.

[17]  Jianrong Li,et al.  Functional antagonism of sphingosine‐1‐phosphate receptor 1 prevents cuprizone‐induced demyelination , 2018, Glia.

[18]  E. Havrdová,et al.  Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]. , 2018, Multiple sclerosis and related disorders.

[19]  M. Mori,et al.  Risk factors for fingolimod-induced lymphopenia in multiple sclerosis , 2018, Multiple sclerosis journal - experimental, translational and clinical.

[20]  H. Weiner,et al.  Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. , 2018, Multiple sclerosis and related disorders.

[21]  A. B. Lyons,et al.  Absence of Tumor Necrosis Factor Supports Alternative Activation of Macrophages in the Liver after Infection with Leishmania major , 2018, Front. Immunol..

[22]  D. Barillà,et al.  Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[23]  M. Sormani,et al.  Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[24]  M. Trojano,et al.  Gender differences in safety issues during Fingolimod therapy: Evidence from a real‐life Relapsing Multiple Sclerosis cohort , 2017, Brain and behavior.

[25]  M. Trojano,et al.  Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients , 2017, Journal of Neuroimmunology.

[26]  Derek K. Jones,et al.  Topographic separation of fornical fibers associated with the anterior and posterior hippocampus in the human brain: An MRI‐diffusion study , 2016, Brain and behavior.

[27]  Alexander Parajeles Vindas,et al.  Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS , 2016, Neurology. Clinical practice.

[28]  H. Hartung,et al.  Disease-modifying therapies and infectious risks in multiple sclerosis , 2016, Nature Reviews Neurology.

[29]  Gregory F. Wu,et al.  Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance , 2015, Multiple sclerosis journal - experimental, translational and clinical.

[30]  H. Hartung,et al.  Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia , 2014, Neurology.

[31]  Ludwig Kappos,et al.  Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial , 2014, The Lancet Neurology.

[32]  D. Arnold,et al.  Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. , 2012, The New England journal of medicine.

[33]  David H. Miller,et al.  Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. , 2012, The New England journal of medicine.

[34]  G. Giovannoni,et al.  Fingolimod modulates microglial activation to augment markers of remyelination , 2011, Journal of Neuroinflammation.

[35]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[36]  E. Havrdová,et al.  Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. , 2018, Multiple sclerosis and related disorders.